Zacks.com on MSN3d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCThe EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...
GlobalData on MSN3d
EC approves BMS’ Opdivo and Yervoy combo for HCCThe European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...
Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy ...
US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus ...
European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...
Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...
MedPage Today on MSN2d
De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBCUse of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...
9h
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback